rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IPSC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
      Nov 12Yahoo FinanceIPSC
      Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

      PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the company will attend the upcoming 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. If you are interested in a 1x1 meeting with the Century Therapeutics team during the conference, please reach ou

      Oct 14Yahoo FinanceIPSC
      Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Glaukos (GKOS) and Praxis Precision Medicines (PRAX)

      Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailIPSCPRAX
      Century Therapeutics advances CNTY-813 islet therapy program

      Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailIPSC
      Century Therapeutics presents preclinical data for T1D therapy
      Oct 2Investing.comIPSC
      Century Therapeutics presents diabetes therapy data at EASD
      Oct 2Investing.comIPSC
      Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC)

      Century Therapeutics' CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression. Find out why IPSC stock is a buy.

      Sep 30Seeking AlphaIPSC
      Century Therapeutics SVP Douglas Carr sells $3,199 in shares
      Sep 15Investing.comIPSC
      Century Therapeutics CTO Gregory Russotti sells $4,992 in stock
      Sep 15Investing.comIPSC
      Century Therapeutics Adds Director, Advances Cell Therapy Pipeline

      Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailIPSC
      Century Therapeutics SVP sells $520 in stock for tax withholding
      Sep 9Investing.comIPSC
      Century Therapeutics appoints Joseph Truitt to board
      Sep 9Investing.comIPSC
      Century Therapeutics Appoints Joseph Truitt to Board of Directors

      PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing

      Sep 9Yahoo FinanceIPSC

      This is the newest page. Registered accounts read further back.